Redefining the Future of Cognitive Health
We are thrilled to announce that our Newmanbrain CEO, Pablo Belmonte, attended the prestigious JP Morgan Healthcare Conference in San Francisco, the most renowned healthcare event in the U.S. The conference, accessible by invitation only, brings together top industry leaders, innovators, and investors from around the world to discuss the latest trends and advancements in healthcare.
A Milestone for Newmanbrain
Our participation in JP Morgan Healthcare Conference is a significant milestone for Newmanbrain. It highlights the growing recognition of our groundbreaking innovation, THEIA, the world’s only highly reliable, non-invasive technology capable of objectively assessing mild cognitive impairment (MCI).
Mild cognitive impairment is a condition that affects millions worldwide and can be a precursor to more serious neurodegenerative diseases such as Alzheimer’s. THEIA offers a transformative approach, providing accurate assessments without the need for invasive procedures, giving healthcare professionals a valuable tool for early detection and intervention.
The Vision Behind THEIA
At Newmanbrain, we believe that the future of healthcare lies in innovations that empower individuals to take control of their health. THEIA is designed with this vision in mind — to improve the diagnosis and management of cognitive health and, ultimately, enhance the quality of life for millions of people suffering from cognitive conditions.
Our goal is not only to improve early detection of MCI but also to support the acceleration of drug development in this space, providing critical data to researchers and pharmaceutical companies.
Together, we can change the future of cognitive health and make a lasting impact on the lives of individuals worldwide.
More Info : https://www.jpmorgan.com/about-us/events-conferences/health-care-conference